CAR-T cell therapy has achieved substantial efficacy in multiple hematological malignancies, but ex vivo cell manufacturing requires a long production cycle and involves complex procedures. The development of targeted in vivo delivery technologies has provided a new engineering pathway for ...
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.